If you have been quoted wildly different prices for what sounds like the same medication, this is usually why. One of them is the FDA-approved product from the manufacturer. The other is a compounded version made by a pharmacy, and the two are not the same thing in any respect that matters.
The situation also changed materially, and a lot of the advice still circulating online describes a world that no longer exists.
Why compounded versions appeared at all
Compounding pharmacies exist for genuine reasons. A patient who needs a medication without a particular dye, or in a liquid form because they cannot swallow a tablet, or in a strength that is not commercially made, is exactly who the rules are written for.
There is a second provision. When a drug is on the FDA’s official shortage list, pharmacies are permitted to make copies of it, on the reasoning that a patient who cannot get a medication at all is worse off than one receiving a version that has not been individually reviewed.
Semaglutide and tirzepatide both spent a long stretch on that list. Demand outstripped what the manufacturers could produce, and compounded versions filled the gap. An entire industry of telehealth prescribing was built on top of that provision, and for a period it was operating within the rules.
What changed
The shortages ended. The FDA declared the tirzepatide shortage resolved toward the end of 2024 and the semaglutide shortage in early 2025, with wind-down periods that ran into that spring.
When a drug leaves the shortage list, the basis for copying it goes away with it. The general rule reasserts itself: a compounding pharmacy may not make what is essentially a copy of a commercially available FDA-approved medication. The supply problem that justified the exception no longer exists, so neither does the exception.
That is the whole of the change, and it is not a subtle one. Compounded semaglutide and tirzepatide did not become slightly less advisable. The legal footing they stood on was removed.
What “not reviewed” actually means
The distinction people tend to miss is that compounded drugs are not approved by the FDA. Not “approved under a lighter process” or “approved as a generic”, but outside the approval system entirely.
An FDA-approved medication has been reviewed for safety and efficacy, and its manufacturing is subject to inspection and to standards for consistency between batches. What is on the label is what is in the vial, in that amount, every time.
A compounded preparation carries none of that. It may be made perfectly well by a careful pharmacy. It may also vary in potency between batches, contain a different salt form of the active ingredient, or arrive in a concentration that makes a dosing error easy. During the boom, the FDA and poison control centres reported dosing errors involving patients drawing up the wrong volume from vials, in some cases by an order of magnitude.
Generic medications are a different thing again and are not part of this argument. A generic has been through an approval process demonstrating equivalence to the branded product. There is currently no generic semaglutide or tirzepatide on the US market, so anything cheaper is not a generic.
Why the price gap exists
Compounded versions were substantially cheaper, and that was the appeal. It is worth being clear-eyed that the saving came from somewhere: not from a more efficient manufacturer, but from skipping the approval, the review, and the quality infrastructure that sits behind the branded product.
For some people that was a reasonable trade during a genuine shortage. It is a harder trade to justify now that the medication is available and the exception has lapsed.
What we do here
Alluring Age prescribes the FDA-approved brand-name medications: semaglutide as Wegovy or Ozempic, and tirzepatide as Zepbound or Mounjaro. We do not prescribe compounded versions.
That decision costs our patients more than the cheapest option available online, and it is worth saying so directly rather than pretending the comparison does not exist. What it buys is a medication whose contents are known and consistent, prescribed by a physician who has seen your bloodwork, with follow-up that catches problems and a plan for what happens when you stop.
Questions worth asking any provider
If you are comparing options, and particularly if you are comparing on price, these will tell you most of what you need to know:
- Is this the FDA-approved medication, or is it compounded? Ask directly. A provider who answers evasively has told you.
- If it is compounded, on what basis, given that the shortage exception has ended?
- Which pharmacy makes it, and is it a 503A or 503B facility?
- What concentration is it supplied at, and how do I measure a dose?
- What bloodwork do you run before prescribing, and who reviews it?
The last one matters more than people expect. A medication that removes appetite will produce weight loss whether or not the reason you gained the weight was ever identified. If an underactive thyroid or a hormonal shift is driving your situation, it is still driving it, and you will find that out when you stop.
A reasonable summary
The medications work. The category is a real advance and it has helped a great many people for whom nothing else did.
The question is no longer whether to take them seriously. It is whether the version you are being offered is the one that was studied, and whether anyone involved has looked at why your weight became difficult in the first place. Those are answerable questions, and it is worth asking them before the price is the thing that decides.
If you want that conversation properly, with the testing in front of you, book a consultation.
